Zobrazeno 1 - 8
of 8
pro vyhledávání: '"M Pedrosa-Ruiz"'
Publikováno v:
Eur J Hosp Pharm
Background Etanercept is a biological drug that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF) with a considerable economic impact on the hospital’s annual budget. Biosimilar therapies are expected to be less costly for healt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1dd133c5d9c483b545240e65b42e4b
https://europepmc.org/articles/PMC7535226/
https://europepmc.org/articles/PMC7535226/
Publikováno v:
Eur J Hosp Pharm
Background Secukinumab has demonstrated efficacy in moderate to severe plaque psoriasis (PP) by improving the Psoriasis Area and Severity Index (PASI), but patients’ quality of life is not always quantified in clinical trials. Purpose To evaluate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5dfa26a532b6f3f679d7290c546f11
https://europepmc.org/articles/PMC7535509/
https://europepmc.org/articles/PMC7535509/
Publikováno v:
Eur J Hosp Pharm
Background Drug shortages are becoming more common and may involve a reduction in pharmacotherapeutic efficacy and increased medication errors. Problems caused by medicines’ shortages are serious, threaten patient care in hospitals and require urge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd04f050d070a3f92d745d5e38023b6d
https://doi.org/10.1136/ejhpharm-2018-eahpconf.47
https://doi.org/10.1136/ejhpharm-2018-eahpconf.47
Publikováno v:
Eur J Hosp Pharm
Background Apremilast is a phosphodiesterase4 inhibitor. Two pivotal trials were carried out comparing apremilast to placebo in plaque psoriasis (PP). At week 16, significantly more patients taking apremilast achieved PASI75 (28.8%–33.1%) in both t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db62288625b87bcb56320be24c23e0a
https://doi.org/10.1136/ejhpharm-2018-eahpconf.251
https://doi.org/10.1136/ejhpharm-2018-eahpconf.251
Publikováno v:
Eur J Hosp Pharm
Background Disease modifying therapies (DMT) for multiple sclerosis (MS) have a considerable economic impact on hospitals’ annual budgets. Since February 2017, there has been a shift of power from our Health Service Area to local MS committees to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48795ef37cf6b015d895c3365962eb69
https://doi.org/10.1136/ejhpharm-2018-eahpconf.15
https://doi.org/10.1136/ejhpharm-2018-eahpconf.15
Autor:
JM Fernández-Ovies, C Estaun-Martinez, I Moya-Carmona, R Mora-Santiago, E Aguilar-Valle, M Pedrosa-Ruiz
Publikováno v:
Clinical pharmacy.
Background The introduction of PCSK9 inhibitors in the treatment of hypercholesterolaemia marks a breakthrough for patients unresponsive to traditional treatment. However, in our country, 44.9% of adults have high LDL-C levels (≥ 130 mg/dL or under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa06d303c80567ed76c8d99977286ff8
https://doi.org/10.1136/ejhpharm-2017-000640.195
https://doi.org/10.1136/ejhpharm-2017-000640.195
Autor:
Mdr Mora-Santiago, Y Dominguez-Rivas, E Aguilar-Valle, L Dani-Ben-Abdel-Lah, C Estaun-Martinez, JM Fernández-Ovies, E Sánchez-Yañez, M Pedrosa-Ruiz, I Moya-Carmona
Publikováno v:
Clinical pharmacy.
Background Macitentan is a new endothelin receptor antagonist (ERA) which was compared with placebo in the SERAPHIN trial. The results showed no superior efficacy or safety compared (indirectly) with other ERAs but better hepatic tolerance. Purpose T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b018aad7ef1546c3c56bbb2a565d7a40
https://doi.org/10.1136/ejhpharm-2017-000640.128
https://doi.org/10.1136/ejhpharm-2017-000640.128
Publikováno v:
Value in Health. 21:S405
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::118841a29d23774dd78c62320e42ce5c
https://doi.org/10.1016/j.jval.2018.09.2403
https://doi.org/10.1016/j.jval.2018.09.2403